Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Begin-Period-Cashflow" stands at 101.14 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
Johnson & Johnson's third quarter result of 18.58 Billion USD for the item "Begin Period Cashflow" represents a decrease of -51.72 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 18.58 Billion USD for the item "Begin Period Cashflow" represents a decrease of -25.33 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 101.14 Billion USD for the item "Begin Period Cashflow" represents a decrease of -5.86 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 10.00 percent compared to the value the year prior.
The 1 year change in percent is 10.00.
The 3 year change in percent is 88.91.
The 5 year change in percent is 67.84.
The 10 year change in percent is 98.43.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Begin Period Cashflow | 905,699,262,464.00 |
![]() | AbbVie Inc - Begin Period Cashflow | 399,570,305,024.00 |
![]() | Roche Holding AG - Begin Period Cashflow | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Begin Period Cashflow | 280,205,508,085.11 |
![]() | Novartis AG - Begin Period Cashflow | 255,096,620,580.91 |